Survival of Patients with Neuroblastoma Treated with 125-I MIBG
Authors:
- Brahm ShapiroBSBrahm Shapiro
- Raymond J. HutchinsonRHRaymond J. Hutchinson
- Barry L. ShulkinBSBarry L. Shulkin
- Shirley ZempelSZShirley Zempel
- 1 April 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 19 (2) , 144-148
Abstract
Recurrent or persistent neuroblastoma in stages III and IV is usually fatal despite modern therapies. Metaiodobenzylguanidine labeled with 131-I (131-I MIBG) concentrates in most neuroblastoma and when given in doses that impart therapeutic radiation, has produced remissions in patients with these tumors. However, success with 131-I MIBG has been limited. The physical characteristics of radiation imparted by 125-I MIBG theoretically could overcome some of the limitations that restrain the therapeutic effects of 131-I MIBG in patients with neuroblastoma. Thereby, 125-I MIBG may offer advantages over 131-I MIBG in the treatment of neuroblastoma. Ten children who manifested persistent/recurrent stage III or IV neuroblastoma were given 8.3 to 30.1 GBq or 224 to 814 mCi of 125-I MIBG in a phase I-II trial. Five of the patients had progression-free survivals > 1 year (continuing in three patients), and four of these subjects are surviving 17 to 52 months after treatment with 125-I MIBG. With appropriate doses of 125-I MIBG, life-threatening toxicity can be avoided. Thus, survivals after 125-I MIBG appear to be as long or longer than those historically observed following other treatments for patients similarly afflicted with refractory neuroblastoma.Keywords
This publication has 12 references indexed in Scilit:
- Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidineEuropean Journal of Nuclear Medicine and Molecular Imaging, 1994
- High-dose consolidation chemotherapy in infants with stage 4 neuroblastomaEuropean Journal of Cancer, 1993
- 131-I-Metaiodobenzylguanidine Treatment in Patients with Refractory Advanced NeuroblastomaAmerican Journal of Clinical Oncology, 1992
- Radiotoxicity of an 125 I-Labeled DNA Intercalator in Mammalian CellsRadiation Research, 1989
- A Method of Calculating Initial DNA Strand Breakage Following the Decay of Incorporated 125 IInternational Journal of Radiation Biology, 1988
- Association of Multiple Copies of the N-mycOncogene with Rapid Progression of NeuroblastomasNew England Journal of Medicine, 1985
- Histopathologic Prognostic Factors in Neuroblastic Tumors: Definition of Subtypes of Ganglioneuroblastoma and an Age-Linked Classification of NeuroblastomasJNCI: Journal of the National Cancer Institute, 1984
- Solid-phase exchange radioiodination of aryl iodides. Facilitation by ammonium sulfateThe Journal of Organic Chemistry, 1982
- FAMILIAL NEUROBLASTOMA WITH REGRESSION AND MATURATION TO GANGLIONEUROFIBROMAPediatrics, 1969
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958